Microbix Biosystems Inc.
MBXBF · OTC
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 10.71 | -5.54 | -0.35 |
| FCF Yield | 5.22% | -4.88% | 2.06% | 1.13% |
| EV / EBITDA | 6.48 | 19.55 | 18.68 | 12.21 |
| Quality | ||||
| ROIC | 10.72% | -8.67% | 8.39% | 18.40% |
| Gross Margin | 60.61% | 45.30% | 58.32% | 59.40% |
| Cash Conversion Ratio | 1.24 | 27.72 | 1.94 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | 10.01% | -3.87% | 21.92% | 11.50% |
| Free Cash Flow Growth | 215.64% | -246.63% | 79.01% | 199.86% |
| Safety | ||||
| Net Debt / EBITDA | -1.06 | -2.54 | -2.30 | -0.40 |
| Interest Coverage | 4.24 | -3.26 | 3.26 | 3.02 |
| Efficiency | ||||
| Inventory Turnover | 1.55 | 1.57 | 1.50 | 1.71 |
| Cash Conversion Cycle | 198.95 | 239.41 | 217.17 | 208.88 |